A variety of new therapeutics targeting HER2, including bispecific antibodies, antibody-drug conjugations (ADC), and immunotherapies, have also entered the clinical testing stage and shown great clinical application potential, which will provide rich options for the treatment of HER2-positive breast cancer [3]. Here, ERBB2 is linked to breast carcinoma.